(Reuters) - Johnson & Johnson reported second-quarter profit and raised its full-year sales forecast by around $2 billion on ...

Veranex, a global provider of product development and contract research services, today introduced the industry’s first ...

Johnson & Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year ...

Johnson & Johnson (NYSE:JNJ) is set to kick off the second quarter pharma earnings on Wednesday, with investors focusing on ...

Johnson & Johnson (NYSE: JNJ) shares ticked up before hours today on second-quarter results that came in ahead of the ...

Despite healthcare spending cuts, medtech stocks like Edwards Life Sciences, Stryker, and Boston Scientific are rising, ...

The year kicked off with a handful of acquisitions from top companies. Dealmaking has since slowed amid economic uncertainty ...

Proximie (the "Company"), the leading global health technology platform digitising operating rooms ("OR"), announces a ...

The Meiban investment represents a strategic and equity partnership, helping Plannet Innovation meet high-volume supply chain needs. Meiban is a manufacturer with 19 sites across Singapore and ...

Clinical trials are the last piece of the puzzle for Ireland’s medtech sector, says University of Galway’s John Kilmartin.

One Six 8 Ventures’ Judyanna Yu explains why capital alone isn’t enough to scale life sciences companies at home.

Medical technology has been on the up for many years, and professionals and experts in Australia have been making strides in innovation over the last decade.